GSTO1‐OE increased cisplatin resistance, whereas GSTO1‐KO or the GSTO1 inhibitor GSTO1‐IN‐1 sensitized bladder cancer to cisplatin (Fig. 3D–F). The gene discussed is GSTO1; the disease is urinary bladder carcinoma.